Overview

TKI258 for Metastatic Inflammatory Breast Cancer Patients

Status:
Completed
Trial end date:
2015-11-25
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if dovitinib can help to control inflammatory breast cancer. The safety of this drug will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Novartis